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1  | INTRODUC TION
Tumor growth and progression are complex processes that involve 
interactions between cancer cells and their surrounding stroma. 
These interactions are required for the formation of the so- called 
tumor microenvironment, which includes numerous types of cells, 
such as fibroblasts and immune cells, as well as acellular components 
such as the extracellular matrix and associated soluble factors.1 
These cells and components of the tumor microenvironment differ 
according to type, developmental stage and location of tumors, and 
function in a context- dependent manner.2
The outcomes of the association between cancer cells and 
stroma lead to positive or negative regulation of tumor progression.3 
When cancer cells appear during the early stage of tumor develop-
ment, the surrounding stroma is mainly composed of normal cells 
that preferentially suppress tumor growth. However, during tumor 
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Tumor growth and progression are complex processes mediated by mutual interac-
tions between cancer cells and their surrounding stroma that include diverse cell 
types and acellular components, which form the tumor microenvironment. In this en-
vironment, direct intercellular communications play important roles in the regulation 
of the biological behaviors of tumors. However, the underlying molecular mechanisms 
are insufficiently defined. We used an in vitro coculture system to identify genes that 
were specifically expressed at higher levels in cancer cells associated with stromal 
cells. Major examples included epithelial membrane protein 1 (EMP1) and stomatin, 
which positively and negatively regulate tumor progression, respectively. EMP1 pro-
motes tumor cell migration and metastasis via activation of the small GTPase Rac1, 
while stomatin strongly suppresses cell proliferation and induces apoptosis of cancer 
cells via inhibition of Akt signaling. Here we highlight important aspects of EMP1, 
stomatin, and their family members in cancer biology. Furthermore, we consider the 
molecules that participate in intercellular communications and signaling transduction 
between cancer cells and stromal cells, which may affect the phenotypes of cancer 
cells in the tumor microenvironment.
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progression, a subpopulation of cancer cells resist stroma- mediated 
suppression, and begin to reprogram and remodel the surrounding 
stroma to support further tumor progression.4 This transition in-
duces tumor progressive activities of stromal cells through epigene-
tic modifications and locally acting signals, which serves as a critical 
driver of malignancy.5 Moreover, the tumor microenvironment ex-
hibits spatiotemporally promotive or suppressive functions that con-
tribute to tumor progression.6
Numerous studies have shown that classical paracrine and en-
docrine signaling via the secretion of soluble factors, including cy-
tokines and growth factors, into the extracellular space contribute 
to the regulation of the tumor microenvironment to suppress or 
promote tumor progression.3,4,7 Furthermore, direct contact be-
tween cancer cells and stromal cells may crucially affect the bi-
ological behavior of cancer cells,8 although few studies focus on 
this process. Therefore, this review article highlights recent find-
ings that illuminate how direct cell- to- cell contact and intercellular 
communication between cancer cells and stromal cells regulate 
the characteristics and behaviors of cancer cells during tumor 
progression.
2  | DIREC T CELL- TO -  CELL CONTAC T- 
INDUCED GENE E XPRESSION IN C ANCER 
CELL S THROUGH THEIR A SSOCIATIONS 
WITH STROMAL CELL S
To determine how stromal cells regulate tumor behavior through di-
rect cell- to- cell contact in the microenvironment, we have recently 
screened for genes that are upregulated in prostate cancer LNCaP 
cells when they directly associate with primary human prostate 
stroma (PrS) cells. For this purpose, we used an in vitro coculture 
system that specifically detects the effect of direct cell- to- cell con-
tact by limiting the effects of soluble factors secreted from cancer 
cells and stromal cells.9 We identified 30 genes that were markedly 
upregulated in cocultured LNCaP cells, including epithelial mem-
brane protein 1 (EMP1) and stomatin, which are associated with the 
plasma membrane. We have determined the functions of these pro-
teins in cancer cells, particularly in prostate cancer cells.9,10 In this 
section, we introduce their detailed roles in cancer biology.
2.1 | EMP1
EMP1 is a member of the growth arrest- specific 3/peripheral myelin 
protein 22 kDa family, which belongs to the tetraspanin superfam-
ily, and has been clarified to regulate membrane blebbing and in-
hibit spinal chondrocyte differentiation in cultured human cells.11,12 
Among the members of this family, the amino acid sequences of 
EMP1, EMP2, and EMP3 are highly conserved and include four 
predicted transmembrane domains, two extracellular domains, and 
small intracellular domains.13 Each protein mediates tumor progres-
sion and suppression in a cancer type- dependent manner.14
As mentioned above, expression of EMP1 is upregulated in pros-
tate cancer LNCaP cells cocultured with PrS cells, and increased 
EMP1 levels promote the progression of prostate cancer in vitro and 
in vivo.9 Gain of function of EMP1 in several types of cancer cells, in-
cluding prostate, breast, and colorectal cancer cells, enhances their 
migration and invasiveness. LNCaP cells stably expressing EMP1 
inoculated into the prostate grands of immunodeficient mice ex-
hibit enhanced tumor metastasis into lymph nodes and lungs, com-
pared with the control LNCaP cells. Primary tumors engrafted in the 
prostate gland similarly proliferate in control and EMP1- expressing 
LNCaP cells, suggesting that EMP1 does not affect tumor growth.
The intracellular domain of EMP1 directly binds to copine- III, 
which triggers an intracellular signaling cascade mediated by the 
protein tyrosine kinase Src and the Rac guanine nucleotide exchange 
factor Vav2 to activate the small GTPase Rac1, resulting in enhanced 
cell migration and invasiveness.9 EMP1 is uniformly distributed on 
the plasma membrane of cancer cells,9 while signaling molecules in-
cluding Src and Rac1 are highly accumulated at the leading edge of 
migrating cells. One possible explanation for this different molecular 
accumulation is that growth factor signals, such as ErbB2 amplifi-
cation,15 might support the recruitment of copine- III to the leading 
edge for inducing its interaction with EMP1 and subsequent activa-
tion of signaling molecules downstream of EMP1 and copine- III. In 
human prostate tumors, higher levels of EMP1 correlate with the de-
gree of malignancy of prostate cancer. Together, these data support 
the conclusion that EMP1 promotes tumor metastasis by enhancing 
the movement of cancer cells (Figure 1). However, insufficient data 
are available to show how EMP1 expression is increased in cancer 
cells through direct association with stromal cells.
These findings have important clinical implications because they 
indicate that the development of a blocking antibody against EMP1 
may inhibit metastasis. For example, inhibition of EMP2, which has 
pro- metastatic functions in certain cancers, by a recombinant anti- 
EMP2 bivalent antibody fragment reduces the aggressiveness of 
endometrial cancer.16 In our preliminary examination, the EMP1 an-
tibody that we generated by using the epitope at the second extra-
cellular loop of this protein showed an approximately 60% reduction 
of prostate cancer cell migration, which may contribute to inhibition 
of tumor metastasis. It is speculated that the binding of this antibody 
to EMP1 might change its conformation, followed by impairment of 
the EMP1- copine- III interaction. Further molecular structural study 
in the future would provide clear evidence for this speculation. In 
addition, small molecules and other agents that block the interaction 
between EMP1 and copine- III may serve as anti- metastatic cancer 
therapeutics.
In contrast with our findings, it has been reported that the 
levels of EMP1 are higher in normal tissues rather than prostate 
tumors, and that overexpression of EMP1 in PC3 prostate can-
cer cells decreases their migration and invasiveness.17 However, 
EMP1 is selected as one of the five novel predictive markers for 
poor outcomes of prostate cancer in African American men.18 
Such a discrepancy in EMP1 function is also observed in breast 
cancer. For example, lobular carcinomas, highly malignant breast 
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F I G U R E  1   EMP1- induced signal 
transduction promotes cancer metastasis. 
Interactions between cancer and stromal 
cells enhance EMP1 expression through 
an unidentified molecular mechanism, 
leading to activation of Rac1 to promote 
the migration of cancer cells and 
subsequent tumor invasion and metastasis
F I G U R E  2   Stomatin- mediated 
inhibitory mechanism of tumor growth. 
A, Schematic models of stomatin. C, 
palmitoylated cysteine; CC, coiled- coil 
domain; IM, intramembrane domain; 
SPFH, stomatin, prohibitin, flotillin, and 
HflK/C domain. B, Increased stomatin 
expression induced by the cancer cell- 
stromal cell contact inhibits Akt activation 
by decreasing PDPK1 expression, 
followed by suppression of cancer cell 
proliferation and induction of apoptosis. 
In contrast, loss of stomatin facilitates 
tumor growth
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tumors, express significantly higher levels of EMP1, compared 
with ductal carcinomas.19,20 In contrast, reduced expression of 
EMP1 is associated with shorter survival of patients with breast 
cancer.21 Furthermore, evidence indicates that EMP1 positively 
and negatively regulates tumor progression, including metastasis, 
depending on tumor type.17,22 Future studies are required to iden-
tify the factor(s) that switches between the tumor progressive and 
suppressive functions of EMP1.
2.2 | Stomatin
Stomatin is a member of the stomatin, prohibitin, flotillin, and 
HflK/C (SPFH) superfamily, which comprises stomatin, stomatin- 
like proteins, prohibitins, flotillin/reggie proteins, and HflK/C 
proteins. Members of the SPFH protein family, which are highly 
conserved among species, are expressed in red blood cells, fi-
broblasts, and cancer cells.23 These proteins localize different 
intracellular compartments including membrane lipid rafts, and 
promote or inhibit diverse cellular functions, such as induction 
of endocytosis and reduction of protein synthesis.24,25 Stomatin 
was originally called “erythrocyte band 7.2b” and later given its 
name “stomatin,” because this protein is not expressed in patients 
with hereditary stomatocytosis, a form of hemolytic anemia.26 
However, different from humans, homozygous deletion of the 
gene encoding murine stomatin causes no obvious physiologically 
significant phenotype in mice.27
Stomatin is a 31 kDa integral membrane protein possessing an 
intramembrane domain, two palmitoylated cysteines and a coiled- 
coil domain in addition to the conserved SPFH domain (Figure 2A), 
and mainly localizes on lipid rafts, to regulate the activities of several 
channels and transporters.28- 30 Furthermore, stomatin is involved 
in the determination of cell morphology through binding to corti-
cal actin in epithelial cells,31,32 and increased expression of stomatin 
promotes cell fusion.33 Together, these findings provide compelling 
evidence that stomatin mediates events that occur on the plasma 
membrane. However, little information is known about the function 
of stomatin in cancer cells.
Similar to EMP1, LNCaP cells cocultured with PrS cells express 
significantly higher levels of stomatin.10 Induction of stomatin ex-
pression in LNCaP and PC3M cells, both of which do not express 
endogenous stomatin in the normal condition, strongly suppresses 
cell proliferation and induces apoptosis, leading to the inhibition of 
tumor growth.10 Stomatin- mediated tumor suppression is caused 
by the inhibition of the Akt signaling pathway, which is crucial for 
cell proliferation and survival.34 Akt activation is mainly induced by 
phosphoinositide- dependent protein kinase 1 (PDPK1), and the sta-
bility of PDPK1 is maintained by its binding to heat shock protein 90 
(HSP90).35 Stomatin binds to PDPK1 and inhibits the formation of the 
PDPK1- HSP90 complex to inhibit PDPK1 expression. Conversely, 
loss of function of stomatin in prostate cancer 22Rv1 cells, which 
express a certain degree of stomatin endogenously on the plasma 
membrane, elevates Akt activation and enhances tumor growth.10 
Clinically, stomatin levels are significantly decreased in human pros-
tate cancers with high Gleason scores, and lower levels of stomatin 
are associated with increased recurrence of prostate cancer after 
surgery.10 These findings demonstrate the tumor- suppressive effect 
of stomatin on cancer cells (Figure 2B).
Consistent with our results, stomatin expression is decreased 
in malignant breast cancer positive for human epidermal growth 
factor receptor 2,36 and stomatin inhibits tumor metastasis of 
non– small- cell lung cancer.37 For other SPFH family members in 
cancer biology, stomatin- like protein 2 enhances the progression 
of several types of cancers,38,39 and its overexpression in cancer 
cells predicts the poor prognosis of patients with colorectal and 
ovarian cancers.40,41 Prohibitin possesses tumor- suppressive and 
promotive functions.42 These activities depend on the intracellu-
lar localization of prohibitin. In the nucleus of a prostate cancer 
cell, prohibitin recruits Rb to suppress the transcriptional activity 
of E2F to inhibit the cell cycle.43 In contrast, localization of pro-
hibitin on the plasma membrane activates c- Raf and promotes cell 
adhesion and migration.44 Flotillin expression, which is increased 
in multiple types of cancer, promotes tumorigenesis.45 Together, 
these findings show that each member of the SPFH family plays 
a different role in tumor progression in a cell type- dependent 
manner.
Although stomatin possesses tumor- suppressive activ-
ity through targeting the HSP90- PDPK1- Akt signaling axis 
(Figure 2B), further studies are required to identify the mecha-
nism of upregulation of stomatin expression in cancer cells subse-
quent to their direct contact with surrounding stromal cells. It has 
been reported that hypoxia and dexamethasone treatment induce 
stomatin expression in lung adenocarcinoma cells, and that dexa-
methasone effectively induces stomatin expression in concert 
with IL- 6 stimulation.31,32,46 The wide range of pharmacological 
effects of dexamethasone against numerous diseases, including 
inflammatory diseases and cancers,47,48 indicate that it may be 
useful for anti- cancer therapy through increasing the expression 
of stomatin. Therefore, identifying the mechanism that regulates 
stomatin expression may lead to the development of novel anti- 
cancer therapeutics via stomatin- mediated tumor- suppressive 
effects.
3  | DIREC T CELL- TO -  CELL CONTAC T- 
MEDIATED REGUL ATION OF TUMOR 
BEHAVIOR
Several types of cell- to- cell contacts and communications occur 
during the direct interaction between cancer cells and stromal 
cells. These events are mainly categorized into the types as follows: 
contact via the molecules of the cell adhesion apparatus, contact 
between membrane- tethered ligands and receptors, and contact 
mediated by tunneling nanotube (TNTs and tumor microtubes (TMs) 
(Figure 3). These molecules exert tumor- suppressive or promotive 
functions, or both, in the tumor microenvironment.8
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3.1 | Intercellular contact via the molecules of the 
cell adhesion apparatus
Adherens junctions and gap junctions, which participate in form-
ing direct connections between neighboring cells including cancer 
cells and stromal cells, are essential for diverse cellular functions.8,49 
Adherens junctions mainly consist of transmembrane cell adhesion 
molecules, such as cadherins and nectins, and scaffold proteins that 
bind to the intracellular region of cell adhesion molecules to sta-
bilize their cell surface localization.50 Invasive cancer cells usually 
contact stromal cells through cell adhesion molecules of adherens 
junctions.51,52
Heterotypic interactions between N- cadherin in cancer- 
associated fibroblasts and E- cadherin in cancer cells generate in-
tercellular physical forces to promote collective invasion of cancer 
cells.52 Expression of E- cadherin in cancer cells often switches to 
that of N- cadherin, particularly during the epithelial- mesenchymal 
transition.53 This switch promotes cancer cell invasiveness and 
metastasis via N- cadherin- enhanced fibroblast growth factor sig-
naling. Such signaling increases the expression and secretion of 
matrix metalloprotease- 9 and the physical contact between cancer 
cells and the endothelium and stroma.54 Invasive cancer cells and 
stromal cells express other cadherins such as cadherin- 11 and cad-
herin- 23, which support the physical contact between cancer and 
stromal cells, contributing to tumor aggressiveness.55,56 Cancer cells 
that express VE- cadherin interact with endothelial cells to promote 
neovascularization.57 Furthermore, such vasculogenicity mediated 
by the cooperation of tumor cells with endothelial cells in the tumor 
microenvironment occurs in several types of aggressive cancers.58
Gap junctions comprise arrays of intercellular channels formed 
by connexin proteins. Connexins are integral membrane proteins that 
constitute a family of 21 members in humans. Connexin- mediated 
junctions permit the bidirectional transfer of ions, metabolites, and 
secondary messengers between adjacent cells.59 Evidence indicates 
that connexins function as tumor suppressors or promoters, depend-
ing on the isoform, tumor stage, and tissue.60 Gap junctions formed 
between cancer cells and immune cells suppress tumor growth.61,62 
Gap junctions between cancer cells and endothelial cells negatively 
regulate angiogenesis and positively regulate metastasis.63,64 The in-
volvement of connexins in establishing intercellular communication 
between malignant tumors and astrocytes provides advantages for 
tumor invasiveness and resistance to chemotherapy via transfer of 
tumor- protective miRNAs and cyclic GMP- AMP (a second messen-
ger that stimulates the production of interferon) from astrocytes to 
cancer cells.65,66
3.2 | Intercellular contact between membrane- 
tethered ligands and their receptors
Direct contact of cancer cells with stromal cells in the tumor micro-
environment is mediated by the interaction between a membrane- 
tethered ligand and its receptor. Eph receptor tyrosine kinases 
and their ligands ephrins bidirectionally signal to mediate tumor 
progression.67 Early during the development of the tumor micro-
environment, the tumor- suppressive effect of Eph- induced signal-
ing is enhanced by ephrins expressed in surrounding normal cells, 
inhibiting the expansion and invasiveness of tumors that express 
Eph receptors.68,69 However, during the late stage, unconven-
tional ephrin- independent Eph signaling activities promote can-
cer progression.70 In addition, activation of EphA4 signaling in 
breast cancer cells is induced by tumor- associated macrophages 
expressing ephrins, facilitating cytokine release from cancer cells 
to sustain the cancer stem cell niche.71 Another signaling between 
membrane- tethered ligands and their receptors is Notch signaling 
between cancer cells and stromal cells that contributes to tumor 
F I G U R E  3   Intercellular communication 
between cancer cells and stromal cells 
mediated by the cell adhesion apparatus, 
membrane- tethered ligands and 
receptors, and tunneling nanotubes (TNTs) 
and tumor microtubes (TMs)
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progression at various stages.72 In colorectal cancer, activation of 
the Notch1 signal triggered by its ligand delta- like ligand 4 in en-
dothelial cells stimulates endothelial transmigration, resulting in 
the promotion of metastasis.73 Endothelial cells provide another 
Notch ligand, Jagged- 1, to activate Notch1 on glioblastoma cells 
to nurture self- renewal of cancer stem- like cells.74 Activation of 
the Notch3 signal in breast and ovarian cancer cells by Jagged- 1 
in their surrounding cells increases their chemotherapy resistance 
and proliferation.75,76
It is well known that the interaction of the membrane- tethered 
ligand programmed cell death- ligand 1 (PD- L1) in cancer cells with 
its receptor PD- 1 in effector T cells suppresses the T cell- mediated 
anti- tumor immune response and induces cancer progression.77 
Furthermore, this interaction may provide cancer cells with multidrug 
resistance by upregulation of P- glycoprotein expression through the 
phosphatidylinositol 3- kinase/Akt and mitogen- activated protein ki-
nase pathways downstream of PD- L1.78
3.3 | Molecules involved in intercellular 
communication mediated by TNTs and TMs
Recently, newly identified types of intercellular communication, 
designated TNTs and TMs, function in normal cells as well as in 
cancer cells (Figure 4). TNTs and TMs are F- actin- containing thin 
membranous channels that differ in size to enable direct commu-
nication between cancer cells and stromal cells over long distances. 
These tubular structures allow the rapid exchange of cellular com-
ponents and molecules, including organelles, vesicles, molecules, 
and ions.79 The formation of TNTs requires a complex comprising 
M- Sec and the GTPase RALA to regulate the generation of F- actin.80 
In macrophages, loss of function of M- Sec disrupts TNT- mediated 
communications with cancer cells, and suppresses invasive tumor 
morphology.81 Deficiency of connexin- 43, which stabilizes the 
connection of TMs to cells, reduces the TM- mediated network 
between tumor cells and astrocytes, resulting in the suppression 
of glioblastoma cell proliferation.82 However, TNTs and TMs are 
newly identified mediators for direct intercellular communications 
and, therefore, further investigations are required to establish their 
importance in the reciprocal interaction between cancer cells and 
stromal cells.
4  | CONCLUSIONS
Cell- to- cell contact- mediated communications between cancer cells 
and surrounding stromal cells direct tumor behavior through promo-
tive or suppressive activities, which often depend on the stage of 
tumor development and the types of tumors and stromal cells. We 
have recently found that the genes encoding EMP1 and stomatin 
are upregulated in cancer cells specifically associated with stromal 
cells. Among the abovementioned three types of direct cell- to- cell 
contacts, cell adhesion might be important for induction of the ex-
pression of EMP1 and stomatin by the following studies. A member 
of epithelial cell adhesion molecule, trophoblast cell surface antigen 
2, maintains the expression of EMP1 in cholangiocarcinoma cells.83 
In stomatin expression, it is upregulated by IL- 6,46 for which secre-
tion is regulated by cell adhesion molecule cadherin- 11 as well as 
inflammatory cytokines.84
Furthermore, EMP1 and stomatin positively and negatively reg-
ulate cancer progression, respectively. Therefore, in addition to the 
actions of extracellularly secreted factors, direct cell- to- cell contact- 
mediated gene expression and direct intercellular communication 
spatiotemporally contribute to the determination of tumor char-
acteristics. Identification of other molecules that mediate mutual 
intercellular communication between cancer and stromal cells may 
provide key insights into the regulation of cancer progression.
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